4,348 Shares of Gilead Sciences, Inc. $GILD Purchased by M Holdings Securities Inc.

M Holdings Securities Inc. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,348 shares of the biopharmaceutical company’s stock, valued at approximately $691,000.

Other institutional investors have also recently made changes to their positions in the company. Persistent Asset Partners Ltd purchased a new position in Gilead Sciences in the 2nd quarter valued at approximately $25,000. Kimelman & Baird LLC purchased a new stake in shares of Gilead Sciences during the second quarter worth $25,000. PFS Partners LLC increased its position in shares of Gilead Sciences by 101.1% during the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 96 shares during the period. Laurel Wealth Advisors LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at $29,000. Finally, Wiser Advisor Group LLC acquired a new stake in shares of Gilead Sciences in the second quarter valued at $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Recent coverage highlights improving growth across Gilead’s business and strong recent results. Its latest reported quarter beat consensus on both earnings and revenue, with revenue up 6.8% year over year. This supports the positive investment case behind the stock’s advance toward a 52-week high. Article: Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
• Positive Sentiment: Analysts have recently raised price targets, including JPMorgan and Wells Fargo to $190, and maintained positive ratings—potential support for investor sentiment. Gilead Sciences analyst and stock information
• Neutral Sentiment: Gilead partner Xilio Therapeutics said it expects to deliver an option data package for its investigational cancer drug efarindodekin alfa to Gilead in the first half of 2027. Any value to Gilead depends on future data and potential payments; the update does not establish a near-term financial benefit. Xilio Therapeutics pipeline update
• Negative Sentiment: An executive vice president sold 3,399 shares, reducing his holdings by about 39%. The sale was made under a pre-arranged trading plan, which may limit its significance as a signal about the company’s outlook. Gilead Sciences insider-trading report
• Negative Sentiment: Vir, a competitor in hepatitis D, reported positive results for its experimental treatment. The news could raise competitive concerns, though the supplied report does not indicate an immediate impact on Gilead’s business. Vir rival advances hepatitis D treatment

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the sale, the insider directly owned 113,684 shares of the company’s stock, valued at approximately $17,759,714.48. This represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the chief financial officer owned 161,096 shares of the company’s stock, valued at $25,166,417.12. This trade represents a 1.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 242,709 shares of company stock valued at $39,503,427 over the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on GILD. TD Cowen lifted their target price on Gilead Sciences from $160.00 to $175.00 and gave the company a “buy” rating in a report on Friday, October 30th. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Barclays cut their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. HSBC increased their price target on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Citigroup lifted their price objective on Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $170.15.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $170.87 on Wednesday. Gilead Sciences, Inc. has a 12 month low of $116.88 and a 12 month high of $176.58. The firm has a market capitalization of $211.94 billion, a PE ratio of -54.07 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. The business’s fifty day moving average price is $154.00 and its 200 day moving average price is $141.34.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same period last year, the business earned $2.47 EPS. Gilead Sciences’s revenue for the quarter was up 6.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post -1.07 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. Gilead Sciences’s payout ratio is currently -103.80%.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.